Advertisement
Canada markets open in 8 hours 37 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7304
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    82.92
    +0.11 (+0.13%)
     

  • Bitcoin CAD

    88,064.54
    -3,669.62 (-4.00%)
     

  • CMC Crypto 200

    1,389.02
    -35.08 (-2.46%)
     

  • GOLD FUTURES

    2,326.00
    -12.40 (-0.53%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,460.25
    -204.25 (-1.16%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,703.07
    -757.01 (-1.97%)
     

  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

Inovio (INO) Up 10.7% Since Last Earnings Report: Can It Continue?

Zacks Equity Research

It has been about a month since the last earnings report for Inovio Pharmaceuticals (INO). Shares have added about 10.7% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Inovio due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

Inovio Misses on Q4 Earnings & Revenues

Inovio incurred a loss of 34 cents per share for the fourth quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago loss of 24 cents.

ADVERTISEMENT

Inovio generated revenues of $2.5 million in fourth-quarter 2018, missing the Zacks Consensus Estimate of $2.69 million. Revenues decreased 71.6% from the year-ago quarter’s figure of $8.8 million due to significantly lower collaboration payments and grants compared to the year-ago period.

Research and development expenses increased 7.3% to $26.4 million due to higher expenses related to clinical studies, partially offset by lower expenses related to the DARPA Ebola grant.

General and administrative expenses decreased 30% to $5.6 million in the fourth quarter.

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed an upward trend in fresh estimates. The consensus estimate has shifted 35.45% due to these changes.

VGM Scores

Currently, Inovio has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Inovio has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Inovio Pharmaceuticals, Inc. (INO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research